Shots:

• The P-III (B7471026) study evaluates the safety & immunogenicity of Prevnar 20 with Pfizer-BioNTech COVID-19 vaccine in 570 adults aged ≥65yrs. with COVID-19
• The results showed that similar responses were obtained for all 20 serotypes of Prevnar 20 with a dose of the Pfizer-BioNTech COVID-19 Vaccine or PBO & responses to a booster dose of the Pfizer-BioNTech COVID-19 Vaccine were also similar with Prevnar 20 or PBO. The safety profile of the Prevnar 20 & COVID-19 booster vaccines was similar to that of the COVID-19 booster dose
• Prevnar 20 received the US FDA’s approval for invasive disease & pneumonia. Additionally, the results from the P-III studies in infants are expected in H2’22

Ref: Pfizer | Image: The Wall Street Journal